Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.
Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JÁF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MÁ, Mascareñas JL, Sainz B Jr. Alcalá S, et al. J Exp Clin Cancer Res. 2024 Jan 27;43(1):33. doi: 10.1186/s13046-023-02931-7. J Exp Clin Cancer Res. 2024. PMID: 38281027 Free PMC article.
Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells.
Alcalá S, Mayoral-Varo V, Ruiz-Cañas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B Jr. Alcalá S, et al. Int J Mol Sci. 2020 Oct 9;21(20):7437. doi: 10.3390/ijms21207437. Int J Mol Sci. 2020. PMID: 33050159 Free PMC article.
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Alors-Perez E, et al. J Exp Clin Cancer Res. 2021 Dec 2;40(1):382. doi: 10.1186/s13046-021-02153-9. J Exp Clin Cancer Res. 2021. PMID: 34857016 Free PMC article.